Non-Current Liabilities
Accrued expenses and other liabilities
Regeneron Pharmaceuticals Accrued expenses and other liabilities decreased by 5.3% to $2.72B in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 21.5%, from $2.24B to $2.72B. Over 5 years (FY 2020 to FY 2025), Accrued expenses and other liabilities shows an upward trend with a 11.8% CAGR.
Analysis
StatementBalance Sheet Statement
SectionNon-Current Liabilities
CategoryEfficiency
SignalContext dependent
VolatilityStable
First reportedQ4 2017
Last reportedQ1 2026Apr 29, 2026
How to read this metric
Significant changes may indicate shifts in operational scale, tax positions, or changes in accounting accruals.
Detailed definition
This category includes various long-term obligations such as accrued interest, taxes, and other operational liabilities...
Peer comparison
Common across all industries; peers report this as other liabilities or accrued expenses.
Metric ID:
non_current_liabilities_accrued_liabilities_and_other_li_e1212fHistorical Data
20 periods
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $2.02B | $2.06B | $2.21B | $2.05B | $1.93B | $1.80B | $2.07B | $2.07B | $2.18B | $2.64B | $2.36B | $2.39B | $2.36B | $2.54B | $2.53B | $2.24B | $2.46B | $2.98B | $2.88B | $2.72B |
| QoQ Change | — | +2.1% | +7.1% | -7.3% | -5.5% | -7.1% | +15.5% | +0.0% | +4.9% | +21.5% | -10.8% | +1.5% | -1.3% | +7.4% | -0.4% | -11.3% | +9.8% | +20.9% | -3.3% | -5.3% |
| YoY Change | — | — | — | — | -4.2% | -12.8% | -6.0% | +1.4% | +12.5% | +47.2% | +13.7% | +15.4% | +8.5% | -4.1% | +7.2% | -6.3% | +4.2% | +17.3% | +13.8% | +21.5% |
Range$1.80B – $2.98B
CAGR+6.5%
Avg YoY Growth+8.1%
Median YoY Growth+7.8%
Current Streak2 quarters decline
Accrued expenses and other liabilities at Other Companies
Frequently Asked Questions
- What is Regeneron Pharmaceuticals's accrued expenses and other liabilities?
- Regeneron Pharmaceuticals (REGN) reported accrued expenses and other liabilities of $2.72B in Q1 2026.
- How has Regeneron Pharmaceuticals's accrued expenses and other liabilities changed year-over-year?
- Regeneron Pharmaceuticals's accrued expenses and other liabilities increased by 21.5% year-over-year, from $2.24B to $2.72B.
- What is the long-term trend for Regeneron Pharmaceuticals's accrued expenses and other liabilities?
- Over 5 years (2020 to 2025), Regeneron Pharmaceuticals's accrued expenses and other liabilities has grown at a 11.8% compound annual growth rate (CAGR), from $1.64B to $2.88B.
- What does accrued expenses and other liabilities mean?
- Miscellaneous long-term obligations including accrued expenses and operational liabilities.